NxStage Continues Global Momentum Through Agreement with Theradial for Distribution of the System One Home Hemodialysis System in France
LAWRENCE, Mass., July 26, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it signed a five-year distribution agreement with Theradial, a leading distributor of renal care products in France.
Under the terms of the agreement, the NxStage System One™ and PureFlow™ dialysate preparation system will be available to dialysis centers throughout France. Theradial, which has eight sales regions throughout France, also has the option to make Medisystems® ButtonHole® needles available to their customers.
"Theradial is very excited to introduce the NxStage System One as an important new treatment option for patients and their providers in France," said Bruno Duval, General Manager of Theradial. "With our extensive distribution network, Theradial looks forward to enhancing patient care by advancing the growth of home hemodialysis throughout France with the NxStage System One."
"We are pleased to work with Theradial in expanding the availability of the System One to France," said Mike Miller, President of International for NxStage Medical, Inc. "This new agreement represents another important step in our efforts to provide more patients worldwide access to the survival, health and quality-of-life benefits of more frequent therapy possible with our System One."
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.
Theradial has been a French distributor of renal care products since 1998, with business extended across dialysis.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release include statements as to the ability of Theradial to expand patient access to the System One in France. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including customer demand for our products worldwide, the ability of Theradial to successfully promote, sell and service our products, customer demand for our products in France and other factors that are discussed in NxStage's Annual Report on Form 10-Q for the quarter ended March 31, 2011 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
SOURCE NxStage Medical, Inc.